Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Ciccolini

Showing results (41-50 of 168) with videos related to

Pageof 17
Sort By:
Clinical Colorectal Cancer|October 6, 2010
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?Joseph Ciccolini, Eva Gross, Laetitia Dahan, et al.
European Journal of Clinical Pharmacology|June 22, 2010
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphismCédric Mercier, Laetitia Dahan, L'houcine Ouafik, et al.
Plos One|September 30, 2022
Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethicAnne Rodallec, Cristina Vaghi, Joseph Ciccolini, et al.
Nature Reviews. Clinical Oncology|November 25, 2015
Computational oncology--mathematical modelling of drug regimens for precision medicineDominique Barbolosi, Joseph Ciccolini, Bruno Lacarelle, et al.
Fundamental & Clinical Pharmacology|July 7, 2025
DPD Ultra-Rapid Metabolizer Status and Efficacy of 5-Fluorouracil Treatment: A Real-World StudyGovind Kallee, Gérard Milano, Florence Duffaud, et al.
British Journal of Clinical Pharmacology|March 14, 2019
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?Godefridus J Peters, Elisa Giovannetti, Richard J Honeywell, et al.
Pharmaceutics|August 16, 2020
Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial ImmunotherapyGuillaume Sicard, Frédéric Fina, Raphaelle Fanciullino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2015
Ang1 and Tie2 are predictive biomarkers for bevacizumab-letterJoseph Ciccolini, Cindy Serdjebi, Dominique Barbolosi, et al.
Current Drug Targets|November 15, 2014
Trastuzumab-induced cardiotoxicity: is it a personalized risk?Gerard A Milano, Emilie Serres, Jean-Marc Ferrero, et al.
Planta Medica|July 31, 2008
Cytotoxic effects of haplamine and its major metabolites on human cancer cell linesSompheary Ea, Sarah Giacometti, Joseph Ciccolini, et al.
Pageof 17

Showing results (41-50 of 168) with videos related to

Sort By:
Pageof 17
Clinical Colorectal Cancer|October 6, 2010
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?Joseph Ciccolini, Eva Gross, Laetitia Dahan, et al.
European Journal of Clinical Pharmacology|June 22, 2010
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphismCédric Mercier, Laetitia Dahan, L'houcine Ouafik, et al.
Plos One|September 30, 2022
Tumor growth monitoring in breast cancer xenografts: A good technique for a strong ethicAnne Rodallec, Cristina Vaghi, Joseph Ciccolini, et al.
Nature Reviews. Clinical Oncology|November 25, 2015
Computational oncology--mathematical modelling of drug regimens for precision medicineDominique Barbolosi, Joseph Ciccolini, Bruno Lacarelle, et al.
Fundamental & Clinical Pharmacology|July 7, 2025
DPD Ultra-Rapid Metabolizer Status and Efficacy of 5-Fluorouracil Treatment: A Real-World StudyGovind Kallee, Gérard Milano, Florence Duffaud, et al.
British Journal of Clinical Pharmacology|March 14, 2019
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?Godefridus J Peters, Elisa Giovannetti, Richard J Honeywell, et al.
Pharmaceutics|August 16, 2020
Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial ImmunotherapyGuillaume Sicard, Frédéric Fina, Raphaelle Fanciullino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2015
Ang1 and Tie2 are predictive biomarkers for bevacizumab-letterJoseph Ciccolini, Cindy Serdjebi, Dominique Barbolosi, et al.
Current Drug Targets|November 15, 2014
Trastuzumab-induced cardiotoxicity: is it a personalized risk?Gerard A Milano, Emilie Serres, Jean-Marc Ferrero, et al.
Planta Medica|July 31, 2008
Cytotoxic effects of haplamine and its major metabolites on human cancer cell linesSompheary Ea, Sarah Giacometti, Joseph Ciccolini, et al.
Pageof 17